The forward P/E of 10.9x implies the market expects earnings growth to reaccelerate, but with revenue growth stagnating, the multiple may be justified only by margin expansion or capital returns. Compared to IDEXX's 45.6x P/E, Zoetis appears cheaper, but its growth profile is more mature, suggesting the discount is warranted. Investors should monitor whether the premium multiple can be sustained without top-line acceleration.

The gross margin improvement suggests a favorable product mix and pricing discipline, but the operating margin decline from 40.2% a year earlier points to rising SG&A and R&D costs. Net margin of 28.0% remains strong, yet the trend is flat, implying that cost growth is offsetting revenue gains. The true earning power is best reflected in operating margin, which shows resilience but not expansion.

The 2026Q2 ROIC spike is largely a mechanical effect of the $9B debt repayment, which reduced invested capital. Over the past two years, ROIC has hovered between 5.8% and 7.4%, indicating a stable but not compounding return profile. ROE improved to 21.7% in 2026Q2, but this is also distorted by the equity base shrinking to $3.1B due to buybacks. The underlying return on capital appears steady, driven by high margins rather than asset efficiency.

The extended DIO suggests Zoetis is holding more inventory, possibly to mitigate supply chain risks, but this ties up cash and pressures working capital. DSO has also crept up to 57 days from 54 days, while DPO remains around 65 days, limiting supplier leverage. The negative working capital changes in seven of the last ten quarters, as noted in cash flow analysis, corroborate the drag. Efficiency improvements would require inventory normalization and faster receivables collection.

The dramatic deleveraging, likely from a one-time debt repayment, has transformed the balance sheet from moderately leveraged to virtually debt-free. Interest coverage of 15.2x is robust, but the prior leverage levels (D/EBITDA around 7-10x) were more typical. This shift reduces refinancing risk and interest expense, but it also suggests a strategic pivot that may not be sustainable if debt is re-leveraged for acquisitions. Investors should monitor whether this is a permanent capital structure change.

The liquidity position is robust, with cash at $1.5B and a current ratio well above 2, suggesting Zoetis can comfortably meet near-term obligations. The quick ratio of 1.84 indicates that even without inventory, liquid assets cover current liabilities. This buffer provides flexibility for capital allocation, but the high inventory levels (DIO of 346 days) could become a liquidity risk if demand softens. Overall, the balance sheet appears well-positioned for stress scenarios.